ERBB2 and neoplasm: Activation of the do-not-eat-me signal has led to clinical success when used in combination with antibodies targeting a tumor antigen such as HER2, CD33, or CD20, demonstrating that an additional push towards a pro-inflammatory response delivered by the tumor-targeting antibody is needed in addition to stimulating phagocytic properties [46,47].